LABU / LABU: A 3X Leveraged ETF Best Avoided

The Direxion Daily S&P Biotech Bull 3x Shares ETF (LABU) is a high-risk, leveraged ETF that aims to yield three times the performance of the S&P Biote more_horizontal

LABU is a 3X leveraged fund that has disappointed the biotech bulls. The sector looks beaten and perhaps cheap relative to long-term prospects. LABU c more_horizontal

Watch the Direxion Daily S&P 500 Biotech Bull 3X Shares (NYSEARCA: LABU) if you want a speculative play in the biotechnology industry with amplified v more_horizontal

Biotech stocks have pulled back and offer better risk to reward for investors, Direxion Daily S&P Biotech Bull 3x Shares ETF is a popular way to trade more_horizontal

The biotech sector deflated, as most sectors did, in the first half of 2022. However, the sector is in the midst of a comeback as mergers and acquisit more_horizontal

I believe small- and mid-cap biotech bottomed in May through June and has outperformed the broader market since then. Biotech continues to show strong more_horizontal

The biotech sector has been rallying as of late, evidenced by the S&P 500 Biotechnology Index up close to 9% within the past month. Of course, as we'v more_horizontal

Since my last coverage in the previous quarter, LABU has been on a free fall for the past 12 weeks and also recorded a huge loss over the past 6. 3X f more_horizontal